INTRODUCTION
Oxytocin is a neuropeptide produced in the paraventricular nucleus of the hypothalamus and primarily associated with parturition [1] . Recently, accumulating studies have illustrated the involvement of oxytocin in modulation of nociception [2] .
The immerging roles of oxytocin as endogenous and exogenous analgesic has been reported in several clinical reports and basic researches using animal models [3] [4] [5] . A clinical study reported that patients suffering from back pain displayed reduced selfreported pain score after receiving oxytocin via intrathecal administration [3] . As oxytocin does not cross blood brain barrier [6] ,
Original Article
Oxytocin produces thermal analgesia via vasopressin-1a receptor by modulating TRPV1 and potassium conductance in the dorsal root ganglion neurons many animal studies aimed to elaborate the spinal mechanisms of oxytocin-mediated analgesia [7] [8] [9] . Previous research has demonstrated the distribution of oxytocin binding receptors in the dorsal horn of spinal cord [10] . Oxytocin has been demonstrated to inhibit transmission of nociceptive signals by enhanced inhibitory GABA signals from interneurons [8] , and by modulating the potassium conductance in spinal dorsal horn neurons [9] .
Another clinical study reported that patients with irritable bowel syndrome exhibited lowered threshold of visceral discomfort by intravenous administration of oxytocin [4] . Thereafter, recent studies have focused on elucidating cellular mechanisms of analgesia induced by peripheral administration of oxytocin. A study with knockout mice demonstrated that intraperitoneal (IP) injection of oxytocin induces analgesia via vasopressin-1a (V1a) receptor [11] . Oxytocin decreases depolarization-induced calcium transients in the dissociated dorsal root ganglion (DRG) neurons of rat model of neuropathic pain [12] , suggesting the possible involvement of calcium channels in oxytocin-mediated peripheral analgesia. Oxytocin inhibits the activity of acid-sensing ion channels in the DRG neurons via V1a receptor [13] .
Given that we still lack a detailed cellular mechanism of oxytocin-induced peripheral analgesia, we examined in the present study how the IP administration of oxytocin produces thermal analgesia. We found that V1a receptor in DRG neurons indeed mediates oxytocin-induced thermal analgesia, and its regulations of transient receptor potential vanilloid 1 (TRPV1) and potassium conductance in the DRG neurons via V1a receptor are likely to contribute to the thermal analgesia.
METHODS

Animals
Male Sprague-Dawley rats (Orient Bio, Korea), aging 6-8 weeks, were used in this study. All the experiments were approved by Institutional Animal Care and Use Committee at Seoul National University (SNU-160216-4) and Institutional Animal Care and Use Committee at Korea University College of Medicine (KO-REA-2016-0022). Animals were housed under a 12-h light/dark cycle. Food and water were available ad libitum.
Drugs
Oxytocin, atosiban, and capsaicin were purchased from SigmaAldrich (USA ]AVP, V1aRA) were generously donated from Dr. M. Manning at the University of Toledo College of Medicine (Toledo, OH, USA). All drugs were diluted to the final concentrations from stock solutions on the day of the experiment. The solutions used in behavioral test were dissolved in normal saline. The solutions used in electrophysiological recordings and calcium imaging were dissolved in external solutions of each experiment except capsaicin which were dissolved in ethanol as a stock solution and further diluted in the extracellular solution when applied.
Thermal nociception assay
We adopted Hargreaves' test for thermal nociception assay [14] . As previously described [15] , thermal pain threshold was measured using radiant heat test. Rats were placed on a glass surface at 23-25°C. A heat source was focused on the mid-third hindpaw of a rat standing on the glass plate with all four feet aground, and paw withdrawal latency was assessed using Series 8, Model 390 (IITC Life Science, US).
Preparation of DRG neurons
Modified from the previous study [16] , rats were anesthetized with isoflurane and then decapitated. The DRGs were taken out from L1-L6 and placed immediately in 4°C HEPES buffered HBSS at pH 7.4. After removing the surrounding connective tissues, the DRGs were minced with fine spring scissors under a microscope and the ganglions were transferred to a 15 ml tube containing 2 ml HEPES buffered HBSS in which 100 mg/ml collagenase and 2.4 U/ml dispase had been dissolved, and incubated at 37°C in a water bath for 40 min. The cells were washed in DMEM containing 10% FBS and 0.5% Penicillin and Streptomycin and triturated with a flame-polished Pasteur pipette to separate cells and remove processes. The dissociated cells were placed on 1 mg/ml poly-Dlysine (Sigma-Aldrich, US)-coated glass cover slips (25 mm in diameter), then maintained at 37°C in an incubator. The dissociated neurons were kept for at least another 4 h before electrophysiological recordings or calcium imaging, and used for the experiments within 36 h. The neurons selected for electrophysiological experiments and single cell RT-PCR were 15-35 μm in diameter. More than 3 rats were sacrificed for the collection of dissociated DRG neurons in each experiment.
Single cell reverse transcription polymerase chain reaction (scRT-PCR)
The cells were harvested into a micropipette with a tip diameter of about 20 μm, put into a tube containing reagents solution, and reverse-transcription was performed using EasyScript Two-Step RT-PCR Kit (ABM Inc, Canada) according to the manufacturer's instruction. Subsequent cDNA product was divided into aliquots of 2 μl and the each was used in separate reactions. All PCR amplifications were performed with nested primers (Table 1) using 2X PCR Taq Plus MasterMix (ABM Inc, Canada) according to manufacturer's protocol. Briefly, the first round of PCR was performed in 50 μl of reaction buffer containing 25 μl MasterMix, 2 μl cDNA, 2 μl "outer" primers. The second round reaction buffer (25 μl) contained 12.5 μl MasterMix, 2 μl product from the first round, and 1 μl "inner" primers. The protocol included a 5 min initial denaturation step at 94°C followed by 40 cycles for the first round or 30 cycles for the second round of 30 s denaturation at 94°C, 30 s annealing at 55-60°C depending on primers, 60 s elongation at 72°C. The reaction was completed with 5 min of final elongation. A negative control was acquired from the pipette that did not collect any cell contents, but were submerged in the extracellular solution. The PCR products were displayed on Loading-STAR (DYNEBIO, Korea) stained, 2% agarose gels. Primers were shown in Table 1 .
Immunocytochemistry
Coverslips cultured 24 h with rat DRG neurons were fixed in 4% formaldehyde solution for 20 min. The DRG neurons were washed with 0.01 M phosphate-buffered saline (PBS) and immunostained with following antibodies. The primary antibodies were rabbit anti-V1a receptor polyclonal antibody (1:400; Alomone Labs, UK) and guinea pig anti-TRPV1 polyclonal antibody (1:500; Novus biologicals, USA), diluted in PBS containing 0.3% Triton X-100, 1% normal donkey serum (Jackson ImmunoResearch Co, USA), incubated overnight at 4°C then incubated for 1 h with donkey anti-guinea pig IgG conjugated with cyanine dye 3 (Cy3, 1:200; Jackson ImmunoResearch Co, USA) and donkey anti-rabbit IgG conjugated with fluorescein-isothiocyanate (FITC, 1:200; Jackson ImmunoResearch Co, USA) diluted in the same buffer as the primary antibody. All rinses before and after the incubations were performed with PBS. Coverslips were photographed using confocal microscope (LSM-700; Zeiss, Germany).
Electrophysiological recordings
Modified from the previous study [17] , whole-cell currentand voltage-clamp recordings were performed to measure action potentials and voltage-gated potassium current respectively. The signals from neurons amplified by Axoclamp-700A amplifier (bandwidth filter set at 10 kHz for current-clamp and 1 kHz for voltage-clamp recordings) were digitized and sampled at 50 μs intervals (Digidata 1440, pClamp 10.3; Molecular Devices). Patch pipettes were pulled from borosilicate capillaries (P-97; Sutter Instruments, USA). The resistance of the pipettes was 3-5 MΩ when filled with the intracellular solution composed of (mM): 140 Kgluconate, 10 HEPES, 2 MgCl 2 , 2 CaCl 2 , 11 EGTA, 4 K 2 -ATP and 0.3 Na 2 -GTP adjusted to pH 7.2-7.3 with KOH, osmolarity 280-285 mOsm. Recording chamber was continuously perfused (1-2 ml/min) with the warm (32-35°C) extracellular solution composed of (mM): 150 NaCl, 4 KCl, 2.5 CaCl 2 , 10 glucose, 2 MgCl 2 , 10 HEPES, and 0.5 tetrodotoxin (TTX, applied for voltage-clamp experiments), adjusted to pH 7.4 with NaOH, osmolarity 290-300 mOsm. Na + -free extracellular solution contained 150 mM Tris instead of Na + and was adjusted to pH 7.4 with HCl [18] . Cadmium chloride (300 μM) was added to the Na + -free extracellular solution for blockade of calcium channels [19] . A small patch of cell membrane underneath the tip of the pipette was aspirated to form a gigaseal. After gigasealing, negative pressure was applied to rupture the membrane for a whole-cell configuration. In voltage-clamp experiments, the membrane voltage was maintained at -60 mV. At the holding potential, the membrane potential was stepped to -110 mV for 200 ms and then a depolarizing ramp pulse to 0 mV at a rate of 110 mV/s (step-and-ramp pulse) was applied. In current-clamp experiments, action potentials were generated by 1000 ms depolarizing current with 100-500 pA. Only cells with a stable resting potential (more negative than -40 mV) were used in this study. Han RT et al
Calcium imaging
As described in the previous study [16] , DRG neurons were loaded with 3 μM of the fluorescent calcium indicator dye Fura-2-AM (dissolved in DMSO, F1201, Thermo Fisher Scientific) for 40 min in an incubator at 37°C and then washed. After washing, the cells on a coverslip were placed on a chamber with a perfusion system (4 channel gravity ALA-VM4, Charles Austen Pump, Dynamax 30) in dark surroundings at room temperature. Regions of interest were defined on a computer connected to a CCD camera and the recording area of which were viewed through an inverted microscope. Fura-2 fluorescence of the cells was recorded at 510 nm during shifting excitation at 340 and 380 nm at 1Hz using Lamda DG4. The ratio of emission at 510 nm from excitation at 340 nm to at 380 nm was analyzed. Only cells with a 340/380 fluorescence ratio difference higher than 0.3 were analyzed. Since our experimental protocol of repeated treatment of capsaicin produced TPRV1 desensitization, Phorbol 12-myristate 13-acetate (PMA) was mixed to the 200 nM capsaicin to the final concentration of 10 μM before the experiment to reduce capsaicin-induced calcium-dependent desensitization of TPRV1 [20] . The cells whose 340/380 ratio increased more than 0.3 in response to capsaicin were considered as capsaicin responsive cells. The cells showing 20% decrease in the second capsaicin response in comparison to the first capsaicin response were considered as oxytocin responsive cells.
Statistical Analysis
Data were expressed as mean±SEM. Behavioral and electrophysiological data were analyzed using ANOVA followed by posthoc Bonferroni's test. Differences with a p<0.05 were considered significant.
RESULTS
Oxytocin-induced thermal analgesia was revered by V1a receptor, but not by oxytocin receptor
We aimed to determine the specific receptor that mediates the oxytocin-induced thermal analgesia in vivo by using Hargreaves' test. Thus, we examined whether the analgesic effect produced by IP injection of oxytocin (1 mg/kg), would be affected by coadministration with OTRA (1 mg/kg), atosiban (1 mg/kg) and V1aRA (1 mg/kg). Paw withdrawal latency after thermal stimuli was significantly increased at 30 and 60 min after the injection of oxytocin (Fig. 1A) . This thermal analgesia induced by oxytocin was significantly reversed by co-injection of 1 mg/kg of V1aRA, vasopressin-1a receptor antagonist, but not with 1 mg/kg of OTRA, oxytocin receptor antagonist (Figs. 1A and B) . Co-application of atosiban, oxytocin and vasopressin receptor antagonist, also showed trends for the reversing effect although not statistically significant (Fig. 1B; p>0 .01, posthoc Bonferroni's test). These results suggest that oxytocin induces thermal analgesia via V1a receptor.
Predominant expression of V1a receptor in TRPV1-positive DRG neurons
Given that TRPV1 is the primary transducer of thermal nociception in DRG neurons [21] , we then examined mRNA expression pattern for oxytocin binding receptors in relation with TRPV1 by using scRT-PCR. We only collected small to medium- sized DRG neurons for scRT-PCR ( Fig. 2A, Supplementary Fig.  1A ). Amongst 54 GAPDH expressing neurons, mRNA transcripts of V1a receptor (n=35/54, 65%), vasopressin-1b receptor (V1b, n=3/54, 6%) and oxytocin receptor (n=1/54, 2%) were expressed in DRG neurons. Vasopressin-2 (V2) receptor mRNA was not detected (n=0/54, 0%) (Fig. 2B) . To examine whether the samples were contaminated by glial cells, we investigated the expression of glial fibrillary acidic protein (GFAP) mRNA and GFAP mRNA was not detected in the V1a receptor expressing neurons (n=0/14, 0%) (Supplementary Fig. 1B) . We also found that 67% (n=23/34) of TRPV1-expressing DRG neurons were also co-expressed with V1a receptor. (Fig. 2C) . Our result also demonstrated that the co-expression of TRPV1 and V1a receptor proteins in the DRG neurons ( Supplementary Fig. 2 ). These findings suggest that V1a receptor activated by oxytocin might transact with TRPV1 to induce thermal analgesia.
Oxytocin decreased capsaicin-induced calcium transient in the DRG neurons via V1a receptor
To verify the functional interaction between oxytocin and TRPV1, we examined effects of oxytocin on capsaicin-induced calcium transients in DRG neurons. A series of repetitive capsa- icin application elicited reproducible calcium transients in DRG neurons with PMA although we observed small desensitization (Fig. 3A) . Our results demonstrated that bath application of 5 μM oxytocin significantly decreased calcium transients induced by capsaicin (Figs. 3B and F) . The co-application of 5 μM oxytocin with either 20 μM atosiban (Figs. 3C and F) or 5 μM V1aRA (Figs.  3D and F) reversed the reducing effect of oxytocin on capsaicininduced calcium transients. We found that 78% (55/70) of capsaicin responsive DRG neurons also responded to oxytocin application (Fig. 3E) . These results suggested that oxytocin-induced thermal analgesia might be attributed to the reduction of TRPV1 activity by oxytocin via V1a receptor.
Oxytocin decreased action potential firing frequency of DRG neurons through V1a receptor
We also investigated effects of oxytocin on the membrane excitability in the small to medium-sized DRG neurons. While oxytocin (5 μM) for 60 s lowered the number of action potential in response to a 300 pA and 1000 ms current injection, the number of action potentials evoked by the current injection returned almost to the control value after 5 min-washout (Fig. 4A) . It is noteworthy that action potentials were observed only at the onset and before the offset of the current pulse, suggesting activation of voltage-gated potassium channels rather than other voltage-gated ion channels. Consistent with our results above, inhibitory effects of oxytocin on the action potential firings were also reversed by atosiban (20 μM, Fig. 4B ) and V1aRA (5 μM, Fig. 4C ). These results again suggest that oxytocin reduce membrane excitability of DRG neurons via V1a receptor.
Oxytocin elicited outward potassium currents and small hyperpolarization-induced inward current in DRG neurons via V1a receptor
As reduction of the number of action potentials indicated regulation of voltage-gated potassium channels, we performed voltage clamp recordings with the small to medium-sized DRG neurons in the presence of 0.5 μM TTX. At a holding potential of -60 mV, the membrane potential was stepped to -110 mV for 200 ms and then a depolarizing ramp pulse to 0 mV at a rate of 110 mV/s (step-and-ramp pulse) was applied (Fig. 5A) . Effects of oxytocin on the membrane current response to the ramp pulse were evaluated as a change in the I-V relationship that was obtained by subtraction of the control response from the response obtained after oxytocin application. Application of oxytocin (5 μM) for 60 s markedly enhanced the outward current activated at membrane potentials more positive than -40 mV (Fig. 5B , left and middle) while it caused a slight increase in hyperpolarization-activated inward current at -110 mV (Fig. 5B, left and middle) . The outward current was recorded in Cd 2+ containing Na + -free external solution ( Supplementary Fig. 3B ). The mean peak current density of the DRG neurons at 0 mV also significantly increased by oxytocin (Fig. 5B, right) . In agreement with our previous results, not only atosiban (20 μM, Fig. 5C ) but also V1aRA (5 μM, Fig. 5D ) inhibited the currents elicited by oxytocin, which would indicate that oxytocin induce the prominent outward potassium current and modest hyperpolarization-induced inward current via V1a receptor.
DISCUSSION
In the present study, we demonstrated that oxytocin reduced TRPV1 activity and increased potassium conductance in small to medium-sized DRG neurons via V1a receptor. These might contribute to the thermal analgesic effect produced by peripheral administration of oxytocin. We also found co-expression of TRPV1 and V1a receptor mRNA, and predominant mRNA expression of V1a receptor over other oxytocin binding receptors such as oxytocin, V1b, and V2 receptors in DRG neurons.
Oxytocin binds to not only oxytocin receptor, but also vari- ous vasopressin receptors such as V1a, V1b and V2 receptors [1, 22] . Oxytocin has been reported to exert its analgesic effects via oxytocin receptor in spinal modulation [7, 23] . However, in Hargreaves' test, we found that oxytocin-induced thermal analgesia was only reversed by V1a receptor antagonist, but not by oxytocin antagonist and oxytocin/vasopressin receptor antagonist. Consistent with our results, previous studies also showed that oxytocin exerts its analgesic effect through V1a receptor rather than oxytocin receptor by using knock-out mice [11, 13] . Drug doses from our study were determined based on the previous study illustrating the dose dependent analgesic effects of intraperitoneal injection of oxytocin [5] . It was interesting to note that the effect of V1a receptor antagonist is much larger than that of oxytocin/ vasopressin receptor antagonist (Fig. 1) . This might be due to the difference in efficacy between drugs. As V1aRA was four times more efficient than atosiban as anti-vasopressor [24] , V1aRA blocked the analgesic effect of oxytocin more efficiently than the same dose of atosiban.
In parallel with results in mouse DRG neurons [11] , mRNA expression of V1a receptor was predominant over other oxytocinbinding receptors such as oxytocin receptor and the other vasopressin receptors in small to medium-sized rat DRG neurons. In addition, mRNA of V1a receptor was also found in two-third of the primary afferent neurons expressing TRPV1, which has been reported to convey the thermal nociception of Hargreaves' test and is expressed in more than fifty percent of DRG neurons and mostly nociceptive C-fibers [21, 25, 26] . However, recently, oxytocin receptor has been reported to colocalize with calcitonin- gene related peptide or isolectin B4in the DRG neurons [27] . This discrepancy is attributed to two possible scenarios. First, although we pulled a considerable amount of DRG neurons (n=54), the number of collected DRG neurons still lacked for unbiased analysis of scRT-PCR. The other is that immunostaining plausibly revealed characteristics of a small population of DRG neurons. Taken together with the observation that oxytocin elicited analgesic effects on thermal pain behavior via V1a receptor, these results suggest that V1a receptor plays a role in thermal analgesia by oxytocin.
To determine whether oxytocin could modulate TRPV1 activity in vitro, we performed calcium imaging. Since our experimental protocol of repeated treatment of capsaicin produced TPRV1 desensitization, we applied PMA to reduce capsaicin-induced calcium-dependent desensitization of TPRV1 [20] . Similar to the results of mRNA transcript analysis by scRT-PCR, we found that three-fourth of the DRG neurons responding to capsaicin also functionally responded to oxytocin treatment in calcium imaging study. Capsaicin-induced depolarization activated various calcium channels other than TRPV1, which possibly contributed to long-lasting calcium responses in the DRG neurons. Reduction of the depolarization by oxytocin might affect the activation of the other calcium channels and subsequently reduce the long-lasting calcium responses. Concentration of oxytocin was determined based on a previous report which showed dose-dependent activity of oxytocin for inhibiting acid-sensing ion channels in vitro [13] .
Many ligands of G-protein coupled receptor (GPCR) such as bradykinin, neurokinin and prostaglandins enhance TRPV1 activity in primary afferent neurons and increase pain sensitivity [28] [29] [30] . However, from calcium imaging experiment, we found that oxytocin reduces TRPV1 activity via V1a receptor, a GPCR, in the DRG neurons. In parallel with our results, resolvin D1 attenuated calcium influx through TRPV1 by modulating GPCR [31] . Modulation of TRPV1 activity was reported to reduce peripheral nociceptor activity and pain [32] . These implicate that GPCR-mediated reduction of TRPV1 activity in the DRG neurons might elicit analgesic effects.
V1a receptor employs not only G-proteins including Gs and Gq but also β-arrestins as intracellular signaling pathways [33, 34] . Activation of V1a receptor induced calcium influx markedly in smooth muscle cells using IP3 intracellular signaling pathway. This would indicate Gq-mediated vasopressin-1 receptor signaling is associated with marked calcium influx. However, in the present study, oxytocin did not evoke any significant calcium transients in DRG neurons (Fig. 3) . One possibility is that V1a receptor may adopt β-arrestin dependent receptor internalization for intracellular signaling. A previous research has revealed that β-arrestin-2desensitize TRPV1 in primary sensory neurons of rats using siRNA knockdown [35] . Furthermore, it has been reported that arrestin activation modifies conductance of potassium channels without efficiently activating G-proteins signaling [36] . Thus, further experiments are required to determine intracellular signaling pathways that mediate the analgesic effect of V1a receptor.
We also found that oxytocin modulates membrane excitability of small to medium-sized DRG neurons. In current-clamp recordings, oxytocin reduced the number of action potential firings evoked by current injection via V1a receptor. In details, oxytocin predominantly inhibited action potentials during the current pulse and firings except at its onset or before its offset. This indicated that the reduction in the number of action potentials was associated with inactivating potassium channels rather than with persistent potassium channels [37, 38] . Next, to confirm whether oxytocin indeed modulates activity of potassium channels, we performed voltage ramp test in the presence of TTX. Oxytocin markedly enhanced potassium outward current and slightly enhanced hyperpolarization-activated inward current in response to the ramp pulse through V1a receptor. Several lines of evidence have addressed the roles of inactivating potassium channels in modulation of nociception [39] [40] [41] . Moreover, the previous study has also reported that potassium channel is involved in the antinociceptive effect of oxytocin in neurons of the spinal cord [9] . Taken together, our results show that oxytocin-induced enhancement of outward potassium currents via V1a receptor is associated with its anti-nociceptive action in DRG neurons.
In conclusion, oxytocin reduces TRPV1 activity and enhances potassium conductance via V1a receptor in DRG neurons, leading to analgesic effect produced by IP injection of oxytocin. These results suggest that peripheral administration of oxytocin might directly produce thermal analgesia, and V1a receptor might be a potential target for peripheral therapeutics to treat certain types of pathological pain conditions with thermal pain.
